

Arianna Gentilini

London School of Economics | Cowdray House 2.06 | London WC2A2AE
a.gentilini@lse.ac.uk | +44 7706549539

Education

- 2020 – present *ESRC-funded Ph.D. candidate, Health Policy and Economics*
Provisional dissertation title: “The role of patient organisations in innovation and access in the rare disease space”
Supervisors: Dr. Panos Kanavos, Prof. Alistair McGuire
London School of Economics and Political Science
- 2017 – 2018 *M.Sc., International Health Policy and Health Economics, with distinction*
Dissertation title: “Physical activity, diet or both to improve type 2 diabetes mellitus risk factors in diabetic and prediabetic adults: a network meta-analysis and microsimulation analysis”
London School of Economics and Political Science
- 2013 – 2016 *B.Sc., International Economics, with honours*
Università degli Studi di Padova

Employment

London

Medical Technology Research Group

London School of Economics and Political Science

2020 – present

Senior Researcher

2018 – 2020

Research Assistant

Investigating factors behind misalignment between country reimbursement decisions and European Society of Medical Oncology ratings for oncology pharmaceutical products

Developed and analysed a database of compound-indication pairs, integrating HTA recommendation and funding decision data from national online databases

Examined factors affecting reimbursement decision timelines and decisions employing survival analysis and multinomial logistic regression techniques across a range of OECD countries

Submitted manuscripts for publication in high-impact peer-reviewed journals

London

Centre for Health Economics and Policy Innovation

Imperial College Business School

2021 – 2022

Visiting Fellow

Collaborated with Professor Marisa Miraldo on a research project investigating the influence of rare disease patient organisations on medical innovation

Analysed a large panel of over 1.5 million observations, incorporating external data from primary and secondary sources

Utilized robust econometric techniques to empirically estimate the impact of patient organisations’ advocacy on R&D in rare diseases

London
2021 – 2022
2020 – 2021

Dolon Limited
Consultant
Senior Analyst

London

Neez E, **Gentilini A**